Pharmacokinetics and tumor localization of111in-labeled HuCC49ΔCH2 in BALB/c mice and athymic murine colon carcinoma xenograft

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 2, 2006, Pages 106-116

  Chinn, Paul C ^a   Morena, Ron A ^a   Santoro, Denise A ^a   Kazules, Timothy ^a   Kashmiri, Syed V S ^b   Schlom, Jeffrey ^b   Hanna, Nabil ^a   Braslawsky, Gary ^a  

^a BIOGEN   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

111In; CH2; Carcinoma; CC49; Chelate; Domain deleted; Monoclonal antibody; Murine; Mx DTPA; Radioimmunotherapy; Radioisotopes; TAG 72

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY CC49 IN 111; MONOCLONAL ANTIBODY IN 111; PENTETATE INDIUM IN 111; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TOXICITY; COLON CARCINOMA; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG UPTAKE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SOLID TUMOR; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BINDING, COMPETITIVE; COLONIC NEOPLASMS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTOXINS; INDIUM RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; PENTETIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33744824668     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.106     Document Type: Article

References (51)

1. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457.
2. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized, controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453.
3. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory, follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262.
4. White C, Halpern S, Parker B, et al. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood 1996;87:3640.
5. DeNardo GL, O'Donnell RT, Rose LM, et al. Milestones in the development of Lym-1 therapy. Hybridoma 1999;18:1.
6. Juweid M, Sharkey R, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995;55:5899S.
7. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)1 tositumomab for relapsed refractory B-cell non-Hodgkin's lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259.
8. 2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med 1990;31:1035.
9. Yokota T, Milenic DE, Whitlow M, et al. Rapid tumor penetration of single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52: 3402.
10. Brouwers A, Mulders P, Oosterwijk E, et al. Pharmacokinetics and tumor targeting of 131-labeled F(ab′)2 fragments of the chimeric monoclonal antibody G250: Preclinical and clinical pilot studies. Cancer Biother Radiopharm 2004;19:466.
11. Hu S, Shively L, Raubitschek A, et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055.
12. Mueller BM, Reisfeld RA, Gilles SD. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA 1990;87: 5702.
13. H2 domain-deleted recombinant immunoglobulin. Int J Cancer 1993;53:97.
14. Thor A, Ouchi N, Szpak CA, et al. Distribution of onco-fetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46: 3118.
15. 131I-CC49 in colorectal cancer. Cancer 1994;73:1057.
16. 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma. Clin Cancer Res 1995;1:1503.
17. Mulligan T, Carrasquillo JA, Chung Y, et al. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1995;1:1447.
18. Divgi CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 1995;36:586.
19. Liu T, Meredith RF, Saleh MN, et al. Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials. Cancer Biother Radiopharm 1997;12:79.
20. Tempero M, Leichner P, Dalrymple G, et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial. J Clin Oncol 1997;15:1518.
21. Murray JL, Macey DJ, Grant EJ, et al. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following α-interferon treatment. Cancer Res 1995;55:5925S.
22. 131I-labeled monoclonal antibody CC49 in breast cancer: A phase II trial. Clin Cancer Res 1997;3:1547.
23. Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994;35:1017.
24. 131I-labeled CC49: Outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 1998;4:643.
25. Meredith RF, Partridge EE, Alvarez RD, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 1996;37:1491.
26. 131I-labeled high-affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 1999;5: 3254S.
27. Slavin-Chiorini DC, Kashmiri SVS, Schlom J, et al. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 1995;1:5957S.
28. Slavin-Chiorini DC, Kashmiri SV, Lee HS, et al. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm 1997;12:305.
29. H2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts. Clin Cancer Res 1999;5:2994S.
30. H2CC49. Cancer Biother Radiopharm 2002;17:219.
31. 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm 2004;19:135.
32. Forero A, Meredith RF, Khazaeli MB, et al. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 2003;18:751.
33. Anderson WT, Strand M. Radiolabeled antibody: Iodine versus radiometal chelates. Natl Cancer Inst Monogr 1987;3:149.
34. Sharkey RM, Motta-Hennessy C, Pawlyk D, et al. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 1990;50:2330.
35. Ugur O, Kostakoglu L, Hui ET, et al. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: Dosimetry calculations incorporating cross-organ beta doses. Nucl Med Biol 1996;23:1.
36. Mirzadeh S, Brechbiel M, Atcher R, et al. Radiometal labeling of immunoproteins: Covalent linkage of 2-(4-isothiocyanatobenzyl) diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconj Chem 1990; 1:59.
37. Brechbiel M, Gansow O, Atcher R, et al. Synthesis of 1-(p- isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies. Inorg Chem 1986;25:2772.
38. Kashmiri SVS, Shu L, Padlan EA, et al. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 1995;14:461.
39. Shu LM, Qi C-F, Schlom J, et al. Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proc Natl Acad Sci USA 1995;90:7995.
40. Müller, R. Calculation of average antibody affinity in antihapten sera from data obtained by competitive radioimmunoassay. J Immunol Meth 1980;34:345.
41. Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Meth 1984; 72:77.
42. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 1999;15:1017.
43. 131I lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: Loss of tumor specificity due to radiolysis. Cancer Biother Radiopharm 2000;15:547.
44. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM-the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023.
45. Pavlinkova G, Booth BJ, Batra SK, et al. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Clin Cancer Res 1999;5:2613.
46. Schultz J, Lin Y, Sanderson J, et al. A tetravalent single-chain antibody-streptavidin fusion protein for pre-targeted lymphoma therapy. Cancer Res 2000;60:6663.
47. Chinn P, Braslawsky G, White C, et al. Antibody therapy of non-Hodgkin's B-cell lymphoma. Cancer Immunol Immunother 2003;52:257.
48. Roselli M, Schlom J, Gansow O, et al. Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal-labeled monoclonal antibodies. Nucl Med Biol 1991;18:389.
49. 90Y radioimmunotherapy. Bioconj Chem 1991;2:187.
50. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 2002;29:431.
51. 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imag 2005;32:264.